DHRHealth Institute for Research and Development
News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial)

Study Status:

Active, Not Recruiting

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The primary objective of this study is to estimate the safety of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC and Child-Pugh B7 liver dysfunction by grade 3-5 adverse event rate.


Principal Investigator
Lee Drinkard, MD
Type of Trial
© 2023 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram